• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by GRAIL Inc.

    8/14/24 4:49:48 PM ET
    $GRAL
    Medical Specialities
    Health Care
    Get the next $GRAL alert in real time by email
    SC 13G 1 d869907dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

     

    GRAIL, INC.

    (Name of Issuer)

    Common Stock, $0.001 par value

    (Title of Class of Securities)

    384747 101

    (CUSIP Number)

    June 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 384747 101    SCHEDULE 13G    Page 2 of 5

     

     1   

     NAME OF REPORTING PERSON

     

     Illumina, Inc.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     4,502,126 (See Note 1)

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     4,502,126 (See Note 1)

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     4,502,126 (See Note 1)

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     14.5% (See Note 2)

    12  

     TYPE OF REPORTING PERSON

     

     CO

     

     

    Note 1:

    On June 24, 2024, Illumina, Inc. (“Illumina”) completed the separation of GRAIL, Inc. (the “Company”) through the distribution of approximately 85.5% of the shares of the Company’s common stock, par value $0.001 (“Common Stock”), to holders of Illumina’s common stock (the “Spin-Off”). Immediately following the Spin-Off, Illumina directly owned 4,502,126 shares, or approximately 14.5%, of the outstanding shares of Common Stock. Pursuant to a Stockholder and Registration Rights Agreement, dated as of June 21, 2024 (the “Stockholder and Registration Rights Agreement”), between Illumina and the Company, Illumina granted to the Company a proxy to vote the shares of Common Stock owned by Illumina immediately after the distribution in proportion to the votes cast by the Company’s other stockholders.

    Note 2:

    The denominator for this calculation is based on 31,049,148 shares of Common Stock outstanding as of August 11, 2024, as reported in the Company’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on August 13, 2024.


    CUSIP No. 384747 101    SCHEDULE 13G    Page 3 of 5

     

    Item 1.    (a)    Name of Issuer:
          GRAIL, Inc.
       (b)    Address of Issuer’s Principal Executive Offices:
          1525 O’Brien Drive, Menlo Park, CA 94025
    Item 2.    (a)    Name of Person Filing:
          Illumina, Inc.
       (b)    Address of Principal Business Office, or if none, Residence:
          5200 Illumina Way, San Diego, CA 92122
       (c)    Citizenship:
          Delaware
       (d)    Title of Class of Securities:
          Common Stock, $0.001 par value
       (e)    CUSIP Number:
          384747 101
    Item 3.    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
       Not applicable.
    Item 4.    Ownership.
       (a)-(c)   
       The responses of the Reporting Person to Rows 5, 6, 7, 8, 9 and 11 in the cover page to this Section 13G are incorporated herein by reference.
       Additional Note: On June 24, 2024, Illumina completed the Spin-Off. Immediately following the Spin-Off, Illumina directly owned 4,502,126 shares, or approximately 14.5% of the outstanding shares of Common Stock. Pursuant to the Stockholder and Registration Rights Agreement, Illumina granted to the Company a proxy to vote the shares of Common Stock owned by Illumina in proportion to the votes cast by the Company’s other stockholders.


    CUSIP No. 384747 101    SCHEDULE 13G    Page 4 of 5

     

    Item 5.    Ownership of Five Percent or Less of a Class.
       Not applicable.
    Item 6.    Ownership of More than Five Percent on Behalf of Another Person.
       Not applicable.
    Item 7.    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
       Not applicable.
    Item 8.    Identification and Classification of Members of the Group.
       Not applicable.
    Item 9.    Notice of Dissolution of Group.
       Not applicable.
    Item 10.    Certifications.
       Not applicable.


    CUSIP No. 384747 101    SCHEDULE 13G    Page 5 of 5

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: August 14, 2024

     

    ILLUMINA, INC.
    By:   /s/ ANKUR DHINGRA
      Name: Ankur Dhingra
      Title: Chief Financial Officer
    Get the next $GRAL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GRAL

    DatePrice TargetRatingAnalyst
    11/12/2025$100.00Neutral → Buy
    Guggenheim
    4/21/2025$32.00Buy
    Canaccord Genuity
    11/27/2024$16.00Equal-Weight
    Morgan Stanley
    11/15/2024Peer Perform
    Wolfe Research
    10/17/2024Neutral
    Guggenheim
    More analyst ratings

    $GRAL
    SEC Filings

    View All

    GRAIL Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - GRAIL, Inc. (0001699031) (Filer)

    11/14/25 6:19:55 AM ET
    $GRAL
    Medical Specialities
    Health Care

    SEC Form 424B5 filed by GRAIL Inc.

    424B5 - GRAIL, Inc. (0001699031) (Filer)

    11/14/25 6:18:50 AM ET
    $GRAL
    Medical Specialities
    Health Care

    SEC Form 424B7 filed by GRAIL Inc.

    424B7 - GRAIL, Inc. (0001699031) (Filer)

    11/13/25 4:23:06 PM ET
    $GRAL
    Medical Specialities
    Health Care

    $GRAL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GRAIL to Present at Piper Sandler 37th Annual Healthcare Conference

    MENLO PARK, Calif., Nov. 18, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, Dec. 2 at 3:00 p.m. ET.  Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event. About GRAIL GRAIL is a healthcare company whose mission is to detect

    11/18/25 4:02:00 PM ET
    $GRAL
    Medical Specialities
    Health Care

    GRAIL Reports Third Quarter 2025 Financial Results

    Q3 U.S. Galleri Revenue Grew 28% Year-Over-Year to $32.6 Million Q3 Galleri Tests Sold Grew 39% Year-Over-Year to More Than 45,000 Galleri PMA Submission to FDA Now Anticipated in Q126 Cash Position of More Than $850 Million Includes Recently Completed Private Placement MENLO PARK, Calif., Nov. 12, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the third quarter of 2025. Total revenue in the third quarter grew 26% year-over-year to $36.2 million

    11/12/25 4:02:00 PM ET
    $GRAL
    Medical Specialities
    Health Care

    GRAIL to Present at 7th Annual Wolfe Research Healthcare Conference

    MENLO PARK, Calif., Nov. 4, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the 7th Annual Wolfe Research Healthcare Conference on Tuesday, Nov. 18 at 10:00 a.m. ET.  Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event. About GRAILGRAIL is a healthcare company whose mission is to detect

    11/4/25 4:02:00 PM ET
    $GRAL
    Medical Specialities
    Health Care

    $GRAL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Freidin Aaron sold $134,402 worth of shares (1,697 units at $79.20), decreasing direct ownership by 0.59% to 284,077 units (SEC Form 4)

    4 - GRAIL, Inc. (0001699031) (Issuer)

    11/19/25 4:08:16 PM ET
    $GRAL
    Medical Specialities
    Health Care

    Large owner Illumina, Inc. sold $79,850,000 worth of shares (1,000,000 units at $79.85), decreasing direct ownership by 22% to 3,502,126 units (SEC Form 4)

    4 - GRAIL, Inc. (0001699031) (Issuer)

    11/18/25 9:33:00 PM ET
    $GRAL
    Medical Specialities
    Health Care

    Chief Executive Officer Ragusa Robert P sold $498,622 worth of shares (7,239 units at $68.88), decreasing direct ownership by 0.99% to 727,388 units (SEC Form 4)

    4 - GRAIL, Inc. (0001699031) (Issuer)

    10/16/25 6:18:02 PM ET
    $GRAL
    Medical Specialities
    Health Care

    $GRAL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    GRAIL upgraded by Guggenheim with a new price target

    Guggenheim upgraded GRAIL from Neutral to Buy and set a new price target of $100.00

    11/12/25 8:52:59 AM ET
    $GRAL
    Medical Specialities
    Health Care

    Canaccord Genuity initiated coverage on GRAIL with a new price target

    Canaccord Genuity initiated coverage of GRAIL with a rating of Buy and set a new price target of $32.00

    4/21/25 8:38:45 AM ET
    $GRAL
    Medical Specialities
    Health Care

    Morgan Stanley initiated coverage on GRAIL with a new price target

    Morgan Stanley initiated coverage of GRAIL with a rating of Equal-Weight and set a new price target of $16.00

    11/27/24 7:29:05 AM ET
    $GRAL
    Medical Specialities
    Health Care

    $GRAL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Ding Chun R bought $1,024,698 worth of shares (78,829 units at $13.00) and acquired $879,900 worth of shares (70,000 units at $12.57) (SEC Form 4)

    4 - GRAIL, Inc. (0001699031) (Issuer)

    10/10/24 7:45:32 PM ET
    $GRAL
    Medical Specialities
    Health Care

    $GRAL
    Leadership Updates

    Live Leadership Updates

    View All

    GRAIL Appoints Sarah Krevans to Board of Directors

    MENLO PARK, Calif., Oct. 21, 2024 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced the appointment of Sarah Krevans to its Board of Directors, effective immediately. Ms. Krevans will also serve as a member of the Board's Audit Committee, Compensation Committee, and Nominating and Governance Committee. Following the appointment of Ms. Krevans, the Board will be composed of five directors, four of whom are independent. Ms. Krevans served as president and CEO of Sutter Health, a Northern

    10/21/24 4:01:00 PM ET
    $GRAL
    Medical Specialities
    Health Care

    Wheels Up Announces Gregory Summe to Join Board of Directors

    Veteran Leader Brings Deep Strategic, Aviation, and Governance Experience to Boardroom ATLANTA, Aug. 8, 2024 /PRNewswire/ -- Wheels Up Experience Inc. (NYSE:UP) today announced that Gregory L. Summe, Managing Partner of Glen Capital Partners LLC, joined its Board of Directors, effective August 7. Summe fills the unexpired term of David Adelman, who is stepping down to focus on other professional pursuits. Summe's initial term as a Class II director will continue until the 2026 annual meeting of the Company's stockholders. He will serve on the Audit and Compensation Committees

    8/8/24 8:05:00 AM ET
    $AVTR
    $GRAL
    $NXPI
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Medical Specialities
    Health Care

    $GRAL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by GRAIL Inc.

    SC 13G - GRAIL, Inc. (0001699031) (Subject)

    11/14/24 3:35:14 PM ET
    $GRAL
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by GRAIL Inc.

    SC 13G - GRAIL, Inc. (0001699031) (Subject)

    11/12/24 4:47:47 PM ET
    $GRAL
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by GRAIL Inc.

    SC 13G/A - GRAIL, Inc. (0001699031) (Subject)

    9/30/24 6:42:39 PM ET
    $GRAL
    Medical Specialities
    Health Care

    $GRAL
    Financials

    Live finance-specific insights

    View All

    GRAIL Reports Third Quarter 2025 Financial Results

    Q3 U.S. Galleri Revenue Grew 28% Year-Over-Year to $32.6 Million Q3 Galleri Tests Sold Grew 39% Year-Over-Year to More Than 45,000 Galleri PMA Submission to FDA Now Anticipated in Q126 Cash Position of More Than $850 Million Includes Recently Completed Private Placement MENLO PARK, Calif., Nov. 12, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the third quarter of 2025. Total revenue in the third quarter grew 26% year-over-year to $36.2 million

    11/12/25 4:02:00 PM ET
    $GRAL
    Medical Specialities
    Health Care

    GRAIL to Announce Third Quarter 2025 Financial Results

    Analyst Day 2025 Webcast to Begin at 11:00 a.m. ET on November 13th MENLO PARK, Calif., Oct. 29, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the third quarter 2025 following the close of market on Wednesday, Nov. 12, 2025. Following the release, company management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss results and business progress. Third Quarter 2025 Webcast and Conference Call DetailsA link

    10/29/25 4:02:00 PM ET
    $GRAL
    Medical Specialities
    Health Care

    /U P D A T E -- GRAIL, Inc./

    In the news release, GRAIL PATHFINDER 2 Results Show Galleri ® Multi-Cancer Early Detection Blood Test Increased Cancer Detection More Than Seven-Fold When Added to USPSTF A and B Recommended Screenings, issued 17-Oct-2025 by GRAIL, Inc. over PR Newswire, we are advised by the company that updated media assets have been attached to the news release. The complete, updated release follows: GRAIL PATHFINDER 2 Results Show Galleri ® Multi-Cancer Early Detection Blood Test Increased Cancer Detection More Than Seven-Fold When Added to USPSTF A and B Recommended Screenings More Than Half of Cancers Detected by Galleri Were Early Stage Approximately Three-Quarters of Galleri-Detected Cancers Do N

    10/17/25 6:08:00 PM ET
    $GRAL
    Medical Specialities
    Health Care